C-type natriuretic peptide in chronic renal failure and its action in humans

T. Igaki, Hiroshi Itoh, S. Suga, N. Hama, Y. Ogawa, Y. Komatsu, M. Mukoyama, A. Sugawara, T. Yoshimasa, I. Tanaka, K. Nakao

Research output: Contribution to journalArticle

56 Citations (Scopus)

Abstract

We have previously reported that C-type natriuretic peptide (CNP), the third member of the natriuretic peptide family, is produced in vascular endothelial cells and acts as an endothelium-derived relaxing peptide. To clarify the clinical significance of CNP in disorders, we examined the plasma level of CNP in patients with various cardiovascular diseases, including chronic renal failure (CRF) patients who were under hemodialysis therapy. We also investigated biological effects of intravenously-administered CNP (0.43 nmol/kg) by bolus injection from the peripheral vein in healthy volunteers and measured systemic hemodynamic variables, plasma levels of CNP, atrial natriuretic peptide (ANP), brain natriuretic peptide (BNP), cGMP, aldosterone and also urine volume, urinary excretions of sodium, potassium, chloride and cGMP. The plasma CNP levels in healthy humans (N = 13) was 1.4 ± 0.6 fmol/ml. In CRF patients, the plasma CNP significantly increased up to 3.0 ± 1.1 fmol/ml. The administration of CNP elicited significant increase of plasma cGMP level (from 4.77 ± 1.25 to 8.33 ± 1.59 pmol/ml 15 min after the administration) and of urinary cGMP excretion (from 30.7 ± 4.3 to 74.9 ± 13.4 nmol/30 min). Intravenously-administered CNP exerted significant diuretic (%increase: +117 ± 85.0), natriuretic, kalliuretic and chloriuretic actions with the increase of endogenous creatinine clearance. CNP also elicited significant hypotensive actions ((Δ)BPs/(Δ)BPd: -4.3 ± 1.3/-4.1 ± 1.0 mm Hg) with the concomitant increase of heart rate (+7.6 ± 2.6 bpm). Plasma aldosterone concentration significantly decreased from 45.4 ± 2.3 to 35.4 ± 4.9 pg/ml 30 minutes after the administration. Taken together, these results suggest a role for CNP in human renal function.

Original languageEnglish
JournalKidney International, Supplement
Issue number55
Publication statusPublished - 1996
Externally publishedYes

Fingerprint

C-Type Natriuretic Peptide
Chronic Kidney Failure
Aldosterone
Natriuretic Peptides
Potassium Chloride
Brain Natriuretic Peptide
Atrial Natriuretic Factor
Diuretics
Sodium Chloride
Endothelium
Renal Dialysis
Veins
Creatinine
Healthy Volunteers

ASJC Scopus subject areas

  • Nephrology

Cite this

Igaki, T., Itoh, H., Suga, S., Hama, N., Ogawa, Y., Komatsu, Y., ... Nakao, K. (1996). C-type natriuretic peptide in chronic renal failure and its action in humans. Kidney International, Supplement, (55).

C-type natriuretic peptide in chronic renal failure and its action in humans. / Igaki, T.; Itoh, Hiroshi; Suga, S.; Hama, N.; Ogawa, Y.; Komatsu, Y.; Mukoyama, M.; Sugawara, A.; Yoshimasa, T.; Tanaka, I.; Nakao, K.

In: Kidney International, Supplement, No. 55, 1996.

Research output: Contribution to journalArticle

Igaki, T, Itoh, H, Suga, S, Hama, N, Ogawa, Y, Komatsu, Y, Mukoyama, M, Sugawara, A, Yoshimasa, T, Tanaka, I & Nakao, K 1996, 'C-type natriuretic peptide in chronic renal failure and its action in humans', Kidney International, Supplement, no. 55.
Igaki, T. ; Itoh, Hiroshi ; Suga, S. ; Hama, N. ; Ogawa, Y. ; Komatsu, Y. ; Mukoyama, M. ; Sugawara, A. ; Yoshimasa, T. ; Tanaka, I. ; Nakao, K. / C-type natriuretic peptide in chronic renal failure and its action in humans. In: Kidney International, Supplement. 1996 ; No. 55.
@article{70e01eb89c6246ef905f5c24a6b5e568,
title = "C-type natriuretic peptide in chronic renal failure and its action in humans",
abstract = "We have previously reported that C-type natriuretic peptide (CNP), the third member of the natriuretic peptide family, is produced in vascular endothelial cells and acts as an endothelium-derived relaxing peptide. To clarify the clinical significance of CNP in disorders, we examined the plasma level of CNP in patients with various cardiovascular diseases, including chronic renal failure (CRF) patients who were under hemodialysis therapy. We also investigated biological effects of intravenously-administered CNP (0.43 nmol/kg) by bolus injection from the peripheral vein in healthy volunteers and measured systemic hemodynamic variables, plasma levels of CNP, atrial natriuretic peptide (ANP), brain natriuretic peptide (BNP), cGMP, aldosterone and also urine volume, urinary excretions of sodium, potassium, chloride and cGMP. The plasma CNP levels in healthy humans (N = 13) was 1.4 ± 0.6 fmol/ml. In CRF patients, the plasma CNP significantly increased up to 3.0 ± 1.1 fmol/ml. The administration of CNP elicited significant increase of plasma cGMP level (from 4.77 ± 1.25 to 8.33 ± 1.59 pmol/ml 15 min after the administration) and of urinary cGMP excretion (from 30.7 ± 4.3 to 74.9 ± 13.4 nmol/30 min). Intravenously-administered CNP exerted significant diuretic ({\%}increase: +117 ± 85.0), natriuretic, kalliuretic and chloriuretic actions with the increase of endogenous creatinine clearance. CNP also elicited significant hypotensive actions ((Δ)BPs/(Δ)BPd: -4.3 ± 1.3/-4.1 ± 1.0 mm Hg) with the concomitant increase of heart rate (+7.6 ± 2.6 bpm). Plasma aldosterone concentration significantly decreased from 45.4 ± 2.3 to 35.4 ± 4.9 pg/ml 30 minutes after the administration. Taken together, these results suggest a role for CNP in human renal function.",
author = "T. Igaki and Hiroshi Itoh and S. Suga and N. Hama and Y. Ogawa and Y. Komatsu and M. Mukoyama and A. Sugawara and T. Yoshimasa and I. Tanaka and K. Nakao",
year = "1996",
language = "English",
journal = "Kidney International, Supplement",
issn = "0098-6577",
publisher = "Wiley-Blackwell",
number = "55",

}

TY - JOUR

T1 - C-type natriuretic peptide in chronic renal failure and its action in humans

AU - Igaki, T.

AU - Itoh, Hiroshi

AU - Suga, S.

AU - Hama, N.

AU - Ogawa, Y.

AU - Komatsu, Y.

AU - Mukoyama, M.

AU - Sugawara, A.

AU - Yoshimasa, T.

AU - Tanaka, I.

AU - Nakao, K.

PY - 1996

Y1 - 1996

N2 - We have previously reported that C-type natriuretic peptide (CNP), the third member of the natriuretic peptide family, is produced in vascular endothelial cells and acts as an endothelium-derived relaxing peptide. To clarify the clinical significance of CNP in disorders, we examined the plasma level of CNP in patients with various cardiovascular diseases, including chronic renal failure (CRF) patients who were under hemodialysis therapy. We also investigated biological effects of intravenously-administered CNP (0.43 nmol/kg) by bolus injection from the peripheral vein in healthy volunteers and measured systemic hemodynamic variables, plasma levels of CNP, atrial natriuretic peptide (ANP), brain natriuretic peptide (BNP), cGMP, aldosterone and also urine volume, urinary excretions of sodium, potassium, chloride and cGMP. The plasma CNP levels in healthy humans (N = 13) was 1.4 ± 0.6 fmol/ml. In CRF patients, the plasma CNP significantly increased up to 3.0 ± 1.1 fmol/ml. The administration of CNP elicited significant increase of plasma cGMP level (from 4.77 ± 1.25 to 8.33 ± 1.59 pmol/ml 15 min after the administration) and of urinary cGMP excretion (from 30.7 ± 4.3 to 74.9 ± 13.4 nmol/30 min). Intravenously-administered CNP exerted significant diuretic (%increase: +117 ± 85.0), natriuretic, kalliuretic and chloriuretic actions with the increase of endogenous creatinine clearance. CNP also elicited significant hypotensive actions ((Δ)BPs/(Δ)BPd: -4.3 ± 1.3/-4.1 ± 1.0 mm Hg) with the concomitant increase of heart rate (+7.6 ± 2.6 bpm). Plasma aldosterone concentration significantly decreased from 45.4 ± 2.3 to 35.4 ± 4.9 pg/ml 30 minutes after the administration. Taken together, these results suggest a role for CNP in human renal function.

AB - We have previously reported that C-type natriuretic peptide (CNP), the third member of the natriuretic peptide family, is produced in vascular endothelial cells and acts as an endothelium-derived relaxing peptide. To clarify the clinical significance of CNP in disorders, we examined the plasma level of CNP in patients with various cardiovascular diseases, including chronic renal failure (CRF) patients who were under hemodialysis therapy. We also investigated biological effects of intravenously-administered CNP (0.43 nmol/kg) by bolus injection from the peripheral vein in healthy volunteers and measured systemic hemodynamic variables, plasma levels of CNP, atrial natriuretic peptide (ANP), brain natriuretic peptide (BNP), cGMP, aldosterone and also urine volume, urinary excretions of sodium, potassium, chloride and cGMP. The plasma CNP levels in healthy humans (N = 13) was 1.4 ± 0.6 fmol/ml. In CRF patients, the plasma CNP significantly increased up to 3.0 ± 1.1 fmol/ml. The administration of CNP elicited significant increase of plasma cGMP level (from 4.77 ± 1.25 to 8.33 ± 1.59 pmol/ml 15 min after the administration) and of urinary cGMP excretion (from 30.7 ± 4.3 to 74.9 ± 13.4 nmol/30 min). Intravenously-administered CNP exerted significant diuretic (%increase: +117 ± 85.0), natriuretic, kalliuretic and chloriuretic actions with the increase of endogenous creatinine clearance. CNP also elicited significant hypotensive actions ((Δ)BPs/(Δ)BPd: -4.3 ± 1.3/-4.1 ± 1.0 mm Hg) with the concomitant increase of heart rate (+7.6 ± 2.6 bpm). Plasma aldosterone concentration significantly decreased from 45.4 ± 2.3 to 35.4 ± 4.9 pg/ml 30 minutes after the administration. Taken together, these results suggest a role for CNP in human renal function.

UR - http://www.scopus.com/inward/record.url?scp=0001656802&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0001656802&partnerID=8YFLogxK

M3 - Article

C2 - 8743538

AN - SCOPUS:0001656802

JO - Kidney International, Supplement

JF - Kidney International, Supplement

SN - 0098-6577

IS - 55

ER -